Combination of mTOR and EGFR Kinase Inhibitors Blocks mTORC1 and mTORC2 Kinase Activity and Suppresses the Progression of Colorectal Carcinoma

Ítems similars

• Combination of mTOR and EGFR kinase inhibitors blocks mTORC1 and mTORC2 kinase activity and suppresses the progression of colorectal carcinoma.
  per: Quan Wang, et al.
  Publicat: (2013-01-01)
• Retraction: Combination of mTOR and EGFR kinase inhibitors blocks mTORC1 and mTORC2 kinase activity and suppresses the progression of Colorectal Carcinoma.
  per: PLOS One Editors
  Publicat: (2025-01-01)
• Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
  per: Feldman, Morris E, et al.
  Publicat: (2009)
• mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition
  per: Limon, Jose J., et al.
  Publicat: (2014)
• mTOR has a developmental stage-specific role in mitochondrial fitness independent of conventional mTORC1 and mTORC2 and the kinase activity
  per: Kalim, Khalid W., et al.
  Publicat: (2017)